Recent Updates
Recently added Catalysts

Exaluren

Phase 2

Alport Syndrome, X-Linked | Small molecule | Other |Eloxx Pharmaceuticals, Inc.|Trials Updated: Sep 30, 2026

Exaluren development status

Highest phase Phase 2
Registered trials 1 across 1 sponsor since Apr 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials1
Total Enrollment24

FDA Designations

No designations recorded

Exaluren clinical trials

Exaluren · 1 trial · 2 indications

Phase 2 1
NCT07523581EXACT Study: A Blinded Study in Patients With Alport Syndrome to Evaluate Exaluren Efficacy and SafetyAlport Syndrome, X-Linked
RECRUITING24 Analytics
PHASE2RECRUITING
EXACT Study: A Blinded Study in Patients With Alport Syndrome to Evaluate Exaluren Efficacy and Safety
Alport Syndrome, X-Linked
NCT0752358124
Unlock trial analytics

Study Endpoints

Primary Endpoints

The change in the degree of podocyte foot process effacement
Baseline to Week 16

Measured in kidney biopsies by the change in the Filtration Slit Density (FSD)

Secondary Endpoints

The percentage change in Urine Protein Creatinine Ratio (UPCR)
Baseline to Week 16
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingQUADRUPLE
ModelSEQUENTIAL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
ExalurenEXPERIMENTAL -
PlaceboPLACEBO_COMPARATOR -

Interventions

NameTypeDescription
ExalurenDRUGExaluren is a synthetic Eukaryotic Ribosome Selective Glycoside (ERSG)
Unlock Study Design Details

Eligibility Criteria

Age Range12 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites11

Inclusion Criteria: * A confirmed diagnosis of X-linked or autosomal recessive Alport Syndrome with a documented nonsense mutation of COL4A5 in a male or nonsense mutation of COL4A3 or COL4A4 (male or female) * eGFR\>40 ml/min/1.73 m2 * Urinary protein based on two spot urine collections \[urine pr...

Countries:United StatesUnited Kingdom
Unlock Eligibility Criteria

Explore more on BiopharmaWatch

Eloxx Pharmaceuticals, Inc. (ELOX)Pipeline, catalysts, financials, insiders and newsBiotech disease mapWho is developing what in each indication, and how crowded it isFDA calendarUpcoming PDUFA dates, AdComs and approval oddsPDUFA calendarEvery scheduled FDA decision date, month by monthHistorical FDA calendarPast decisions and how the stock moved on eachCatalyst SyncUpcoming readouts and decisions, screened by runway and phaseBiotech stock screenerFilter by clinical phase, cash runway and market capDrugs A to ZEvery drug page starting with ECompanies A to ZEvery biotech and pharma company we track